Valemetostat (formerly known as DS-3201; DS-3201b) is a first-in-class, investigational and oral EZH1/2 dual inhibitor with anticancer activity. It targets epigenetic regulation by inhibiting the EZH1, as well as EZH2 enzymes, which regulate gene expression by acting through histone methylation. A new drug application seeking the approval of valemetostat tosylate (DS-3201b) for use in the treatment of patients with relapsed/refractory adult T-cell leukemia/lymphoma (ATL) has been submitted to the Japanese Ministry of Health, Labour, and Welfare. Valemetostat is being evaluated in Phase I clinical development for several types of NHLs, including ATL, peripheral T-cell lymphoma (PTCL) and B-cell lymphomas.

纯度：≥98%

CAS：1809336-39-7